193 related articles for article (PubMed ID: 25362349)
1. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
2. β-1,4-Galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma.
Chang HH; Chen CH; Chou CH; Liao YF; Huang MJ; Chen YH; Wang WJ; Huang J; Hung JS; Ho WL; Jeng YM; Che MI; Lee H; Lu MY; Yang YL; Jou ST; Lin DT; Lin KH; Hsu WM; Huang MC
Clin Cancer Res; 2013 Apr; 19(7):1705-16. PubMed ID: 23444218
[TBL] [Abstract][Full Text] [Related]
3. Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Liu SY; Shun CT; Hung KY; Juan HF; Hsu CL; Huang MC; Lai IR
Oncotarget; 2016 Mar; 7(10):11251-62. PubMed ID: 26848976
[TBL] [Abstract][Full Text] [Related]
4. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
5. B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.
Ho WL; Che MI; Chou CH; Chang HH; Jeng YM; Hsu WM; Lin KH; Huang MC
Cancer Sci; 2013 Dec; 104(12):1600-8. PubMed ID: 24118321
[TBL] [Abstract][Full Text] [Related]
6. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Sun Z; Xue H; Wei Y; Wang C; Yu R; Wang C; Wang S; Xu J; Qian M; Meng Q; Li G
Clin Sci (Lond); 2019 May; 133(10):1167-1184. PubMed ID: 31076460
[TBL] [Abstract][Full Text] [Related]
7. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
8. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
[TBL] [Abstract][Full Text] [Related]
9. B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma.
Hsu WM; Che MI; Liao YF; Chang HH; Chen CH; Huang YM; Jeng YM; Huang J; Quon MJ; Lee H; Huang HC; Huang MC
Am J Pathol; 2011 Sep; 179(3):1394-404. PubMed ID: 21741930
[TBL] [Abstract][Full Text] [Related]
10. Expression of GALNT2 in human extravillous trophoblasts and its suppressive role in trophoblast invasion.
Liao WC; Chen CH; Liu CH; Huang MJ; Chen CW; Hung JS; Chou CH; Chen CH; Che MI; Chang HM; Lan CT; Huang HC; Tseng GF; Shyu MK; Huang MC
Placenta; 2012 Dec; 33(12):1005-11. PubMed ID: 23117232
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas.
Weber A; Huesken C; Bergmann E; Kiess W; Christiansen NM; Christiansen H
Clin Cancer Res; 2003 Nov; 9(15):5683-92. PubMed ID: 14654552
[TBL] [Abstract][Full Text] [Related]
13. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.
Hu Q; Tian T; Leng Y; Tang Y; Chen S; Lv Y; Liang J; Liu Y; Liu T; Shen L; Dong X
Cell Mol Biol Lett; 2022 Sep; 27(1):71. PubMed ID: 36058918
[TBL] [Abstract][Full Text] [Related]
14. Identification of DDX39A as a Potential Biomarker for Unfavorable Neuroblastoma Using a Proteomic Approach.
Otake K; Uchida K; Ide S; Kobayashi Y; Kobayashi I; Kusunoki M
Pediatr Blood Cancer; 2016 Feb; 63(2):221-7. PubMed ID: 26469522
[TBL] [Abstract][Full Text] [Related]
15. The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Hu WT; Yeh CC; Liu SY; Huang MC; Lai IR
Am J Cancer Res; 2018; 8(9):1739-1751. PubMed ID: 30323967
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin expression in neuroblastoma--a novel independent prognostic factor.
Hsu WM; Hsieh FJ; Jeng YM; Kuo ML; Chen CN; Lai DM; Hsieh LJ; Wang BT; Tsao PN; Lee H; Lin MT; Lai HS; Chen WJ
Ann Oncol; 2005 Feb; 16(2):314-21. PubMed ID: 15668290
[TBL] [Abstract][Full Text] [Related]
17. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.
Yco LP; Geerts D; Koster J; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329
[TBL] [Abstract][Full Text] [Related]
18. ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression.
Watanabe Y; Ishizuka Y; Hirano T; Nagasaki-Maeoka E; Hoshi R; Yoshizawa S; Uekusa S; Kawashima H; Sugito K; Shinohara K; Fukuda N; Nagase H; Soma M; Koshinaga T; Fujiwara K
Med Oncol; 2017 Aug; 34(9):158. PubMed ID: 28791558
[TBL] [Abstract][Full Text] [Related]
19. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Zhou X; Xu Y; Yin D; Zhao F; Hao Z; Zhong Y; Zhang J; Zhang B; Yin X
Biomed Pharmacother; 2020 Nov; 131():110764. PubMed ID: 33152927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
